How much funding has Ternary Therapeutics raised?

Ternary Therapeutics has raised $4.4M in total funding, most recently a Seed round.

Who are Ternary Therapeutics's investors?

Ternary Therapeutics's investors include Daphni, Pace Ventures, UK Innovation & Science Seed Fund.

When was Ternary Therapeutics founded?

Ternary Therapeutics was founded in 2024.

Where is Ternary Therapeutics headquartered?

Ternary Therapeutics is headquartered in London, United Kingdom.

What industry is Ternary Therapeutics in?

Ternary Therapeutics operates in Biotech, Artificial Intelligence.

How many employees does Ternary Therapeutics have?

Ternary Therapeutics has 1-10 employees.

Ternary Therapeutics

Molecular glues, engineered from the surface up

London, United Kingdom · Founded 2024 · $4.4M raised

Biotech

Artificial Intelligence

Headquarters: London
Employees: 1–10
Founded: 2024
Business Model: B2B

Website: ternarytx.co.uk
Total Funding: $4.4M
Last Round: $4.4M SeedMar 2026
Rounds: 1

About

Ternary Therapeutics (TernaryTx) is a London-based biotech company founded in 2024 that uses frontier AI and deep physics to design molecular glue therapeutics — small molecules that work by glueing two proteins together. Its proprietary four-engine computational platform (Leopard, Puffin, Gecko, Octopus) combines machine learning, physics-based molecular modelling, and rapid laboratory testing to turn molecular glue drug discovery from a chance-based process into a repeatable engineering system. The company has a pipeline of preclinical programmes in inflammatory and neuroinflammatory diseases and raised a €4.1 million seed round in March 2026 led by daphni.

Summary

Ternary Therapeutics is a Biotech company based in London, United Kingdom, founded in 2024. It has raised $4.4M in total across 1 round, most recently a $4.4M Seed round in Mar 2026. Investors include Daphni, Pace Ventures and UK Innovation & Science Seed Fund.